Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2871937 | 0.86 | MAPT (0.62) | USP2ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL13744610 | 0.85 | ALDH1A1 (0.55) | USP2POLBALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL15518189 | 0.85 | ALDH1A1 (0.58) | USP2POLBALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2010417 | 0.84 | USP2 (0.67) | USP2ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL201784 | 0.84 | MEN1 (0.59) | NLRP3POLBALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL14252838 | 0.83 | USP2 (0.57) | NLRP3USP2ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL18702974 | 0.83 | USP2 (0.51) | NLRP3USP2ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2058956 | 0.81 | NLRP3 (0.57) | NLRP3USP2ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL2059383 | 0.81 | POLB (0.58) | POLBALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL9121089 | 0.81 | ALDH1A1 (0.57) | USP2POLBALDH1A1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019008154-A1 | 3-(AZOLYLMETHOXY)BIPHENYL DERIVATIVES AS INHIBITORS OF THE PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2019-01-10 | — | — | WO | disclosed |
| US-9062028-B2 | Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062028-B2 | Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062028-B2 | Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-03-20 | — | — | US | disclosed |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-03-20 | — | — | US | disclosed |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-03-20 | — | — | US | disclosed |
| EP-2702042-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2014-03-05 | — | — | EP | disclosed |
| CN-103619817-A | Novel bicyclic nitrogen containing heteroaryl TGR5 receptor modulators | BRISTOL MYERS SQUIBB CO | 2014-03-05 | — | — | CN | disclosed |
| WO-2012149236-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20050234096-A1 | Tetrahydroisoquinoline derivatives | BAYER HEALTHCARE AG (DE) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | GRK5, GPBAR1, GPR55 | NLRP3 2328/4885USP2 2847/4885POLB 3238/4885 |
| US-20050234096-A1 | Tetrahydroisoquinoline derivatives | PPARD, PPARG, PPARA | NLRP3 1487/4885USP2 3501/4885POLB 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.